Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2024-11-25 Share Issue/Capital Cha…
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
113年11月變更登記
Share Issue/Capital Change Classification · 95% confidence The document is a brief disclosure from a listed company (美時) providing details about its capital stock, including authorized capital, paid-in capital, and changes in capital structure. It includes specific numeric data about shares and capital amounts but does not contain financial statements, management discussion, or detailed financial performance data. The document length is only 846 characters, indicating it is a short announcement rather than a full report. There is no indication of an annual or interim report, audit report, or earnings release. The content focuses on capital stock details, which aligns with announcements about share capital changes or capital structure updates. Therefore, the document is best classified as a Share Issue/Capital Change announcement (SHA).
2024-11-25 Chinese
113年11月僑外投資持股
Major Shareholding Notification Classification · 95% confidence The document is a statistical table showing the shareholding situation of overseas and mainland China investors, including detailed numbers of shares held and changes before and after certain dates. It includes data on foreign and mainland investors' holdings, changes due to shareholder meetings, and total shares issued. There is no indication of this being a report like an annual or interim report, nor is it an announcement of voting results or management changes. The document is a regulatory disclosure of shareholding information, which fits the definition of a Major Shareholding Notification (MRQ). The document length is short and focused on shareholding data, consistent with MRQ filings.
2024-11-22 Chinese
113年11月法人說明會簡報 — 179520241115E001.pdf
Investor Presentation Classification · 95% confidence The document is titled 'LOTUS PHARMACEUTICAL Investor meeting Presentation 1795.TT November 2024' and contains detailed financial results for the third quarter of 2024 (3Q24), including revenue, gross profit, net income, EPS, margins, and segment performance. It also includes business highlights, acquisitions, R&D pipeline information, and business outlook. The content is structured as a presentation with slides covering financial performance, business achievements, and future plans. The presence of forward-looking statements and detailed financial metrics aimed at investors indicates this is an investor presentation rather than a formal earnings release or annual report. The document length (12,344 characters) and detailed content support this classification. Therefore, the document is best classified as an Investor Presentation (IP).
2024-11-18 Chinese
113年11月法人說明會簡報 — 179520241115M001.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled as an "Investor Report" for the third quarter of 2024 and contains detailed financial data including consolidated revenue, gross profit, net profit, EPS, and segment revenue breakdowns. It also includes operational highlights, market outlook, ESG ratings, and acquisition updates. The presence of comprehensive financial statements and analysis for a specific quarter (3Q24) indicates this is a quarterly financial report. The length of the document (9522 characters) and the detailed financial content confirm it is not a brief announcement or a simple presentation. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-11-18 Chinese
113年11月法人說明會簡報 — 179520241118E001.pdf
Investor Presentation Classification · 95% confidence The document is titled 'LOTUS PHARMACEUTICAL Investor meeting Presentation 1795.TT November 2024' and contains detailed financial results for the third quarter of 2024 (3Q24), including revenue, gross profit, net income, EPS, margins, and segment performance. It also includes business highlights, acquisitions, R&D pipeline information, and business outlook. The content is structured as a presentation with slides covering financial performance, business achievements, and future plans. The presence of forward-looking statements, detailed financial metrics, and strategic business updates aimed at investors strongly indicates this is an investor presentation. It is not a full annual or quarterly report, audit report, or earnings release, but a detailed presentation for investors focusing on financials, strategy, and market position.
2024-11-18 Chinese
113年11月法人說明會簡報 — 179520241118M001.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled as an "Investor Report" for the third quarter of 2024 and contains detailed financial data including consolidated revenue, gross profit, net profit, EPS, and segment revenue breakdowns. It also includes operational highlights, market outlook, and ESG ratings. The presence of comprehensive financial statements and analysis for a quarter, along with management commentary on business performance and outlook, indicates this is a quarterly financial report. The document length is 9522 characters, which is substantial and contains actual financial data, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-11-18 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.